News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,549 Results
Type
Article (42012)
Company Profile (331)
Press Release (667206)
Section
Business (210220)
Career Advice (2083)
Deals (36600)
Drug Delivery (100)
Drug Development (82890)
Employer Resources (171)
FDA (16508)
Job Trends (15367)
News (355592)
Policy (33839)
Tag
Academia (2574)
Alliances (51266)
Alzheimer's disease (1308)
Approvals (16469)
Artificial intelligence (178)
Bankruptcy (364)
Best Places to Work (11737)
Biotechnology (213)
Breast cancer (207)
Cancer (1557)
Cardiovascular disease (128)
Career advice (1742)
CAR-T (108)
Cell therapy (318)
Clinical research (66486)
Collaboration (590)
Compensation (312)
COVID-19 (2621)
C-suite (136)
Data (1483)
Diabetes (193)
Diagnostics (6286)
Earnings (86724)
Employer resources (149)
Events (113227)
Executive appointments (502)
FDA (17296)
Funding (526)
Gene therapy (227)
GLP-1 (658)
Government (4460)
Healthcare (18921)
Infectious disease (2718)
Inflammatory bowel disease (118)
Interviews (320)
IPO (16671)
Job creations (4052)
Job search strategy (1488)
Layoffs (445)
Legal (8336)
Lung cancer (228)
Manufacturing (224)
Medical device (13319)
Medtech (13324)
Mergers & acquisitions (20183)
Metabolic disorders (514)
Neuroscience (1682)
NextGen: Class of 2025 (6631)
Non-profit (4519)
Northern California (1882)
Obesity (293)
Opinion (211)
Patents (137)
People (58617)
Phase I (20606)
Phase II (29253)
Phase III (21925)
Pipeline (618)
Postmarket research (2652)
Preclinical (8740)
Radiopharmaceuticals (245)
Rare diseases (302)
Real estate (6244)
Regulatory (22641)
Research institute (2361)
Resumes & cover letters (358)
Southern California (1626)
Startups (3716)
United States (16878)
Vaccines (599)
Weight loss (210)
Date
Today (175)
Last 7 days (417)
Last 30 days (1965)
Last 365 days (35368)
2025 (1834)
2024 (35807)
2023 (40632)
2022 (51801)
2021 (56330)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (210)
Asia (40276)
Australia (6444)
California (4288)
Canada (1568)
China (372)
Colorado (196)
Connecticut (208)
Europe (85738)
Florida (609)
Georgia (147)
Illinois (424)
Indiana (250)
Maryland (695)
Massachusetts (3340)
Michigan (185)
Minnesota (319)
New Jersey (1204)
New York (1212)
North Carolina (808)
Northern California (1882)
Ohio (155)
Pennsylvania (1007)
South America (1159)
Southern California (1626)
Texas (630)
Utah (122)
Washington State (435)
709,549 Results for "actinium pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Actinium Pharmaceuticals, Inc. announced that it has launched a strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 leveraging its propriety cyclotron-based method.
March 11, 2024
·
6 min read
Cancer
Actinium to Farm Out AML Radioactive Drug After FDA Asks for Another Trial
The FDA is looking for stronger overall survival data to back Actinium’s application for Iomab-B, an investigational therapy that will allow acute myeloid leukemia patients to receive bone marrow transplants.
August 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
January 13, 2025
·
5 min read
Pharm Country
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Actinium Pharmaceuticals, Inc. today announced it will host a KOL webinar on Monday, May 20, 2024, at 8:00 AM ET.
May 15, 2024
·
6 min read
Drug Development
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actinium Pharmaceuticals, Inc. announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium’s ARC Actimab-A in acute myeloid leukemia models was presented at the 2024 European Hematology Association Congress held June 13 – 16, 2024, in Madrid, Spain.
June 17, 2024
·
5 min read
Drug Development
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) today highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 – 11, 2024, in Toronto, Canada.
June 11, 2024
·
5 min read
Drug Development
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.
June 14, 2024
·
5 min read
Policy
BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
BWXT Medical Ltd. has submitted a Drug Master File to the U.S. Drug and Food Administration for No Carrier Added Actinium-225 Active Pharmaceutical Ingredient.
June 7, 2024
·
3 min read
Pharm Country
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.
February 26, 2024
·
6 min read
Press Releases
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
November 13, 2024
·
8 min read
1 of 70,955
Next
